Corrigendum: Time to clinical improvement: an appropriate surrogate endpoint for pulmonary arterial hypertension medication trials

• An Wang,
• Mengqi Chen,
• Qi Zhuang,
• Lihua Guan,
• Weiping Xie,
• Lan Wang,
• Wei Huang,
• Zhaozhong Cheng,
• Shiyong Yu,
• Hongmei Zhou,
• Jieyan Shen

Affiliations

An Wang

Department of Cardiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

Mengqi Chen

Department of Cardiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

Qi Zhuang

Department of Cardiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

Lihua Guan

Department of Cardiology, Shanghai Institute of Cardiovascular Disease, Zhongshan Hospital, Fudan University, Shanghai, China

Weiping Xie

Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Lan Wang

Department of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China

Wei Huang

Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Zhaozhong Cheng

Respiratory Department, The Affiliated Hospital of Qingdao University, Qingdao, China

Shiyong Yu

Department of Cardiology, The Second Affiliated Hospital, Third Military Medical University (Army Medical University), Chongqing, China

Hongmei Zhou

Congenital Heart Disease Center, Wuhan Asia Heart Hospital, Wuhan University of Science and Technology, Wuhan, China

Jieyan Shen

Department of Cardiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China